Alnylam Pharmaceuticals

World Rank (Aug-2026)

855

Market Cap (Aug-2026)

30.595 Billion USD

World Rank (Jan-05-2024)

763

Market Cap (Jan-05-2024)

24.134 Billion USD

World Rank (Jul-30-2023)

762

Market Cap (Jul-30-2023)

24.817 Billion USD

World Rank (Jan-07-2022)

1,156

Market Cap (Jan-07-2022)

17.716 Billion USD

World Rank (Jan-01-2021)

1,185

Market Cap (Jan-01-2021)

15.100 Billion USD

Company Rank in Country in 2023

Rank in USA in July-2023 is 325

Headquarters Country

USA

Top Technology Companies in USA

Top Healthcare Companies in USA

Top Pharmaceutical Companies in USA

Top Bio Pharmaceutical Companies in USA

Nasdaq / NYSE Code

ALNY

CEO

John Maraganore

Employee Count

2,002

Employee Count as of Date

As on 2022

Headquarters City/State

Massachusetts

World Region

Americas

World Subregion

Northern America

Annual Revenue in USD

3,714 Million USD

Annual Operating Income in USD

502 Million USD

Annual Net Income in USD

314 Million USD

Annual Results for Period Ending

For year ending December-2025

Total Assets in USD

4,966 Million USD

Total Liabilities in USD

4,177 Million USD

Total Equity in USD

789 Million USD

Balance Sheet for Period Ending

As of December-2025

Business Sector

Company Website

ALNYLAM PHARMACEUTICALS INC

Wikipedia

Yahoo

Yahoo @ Nasdaq

Company Profile

ALNYLAM PHARMACEUTICALS is Biopharmaceutical company with headquarters is in Massachusetts, USA.ALNYLAM leaders from the biopharmaceutical industry, bringing together their experiences of drug discovery, drug development, and commercialization.Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an innovative, entirely new class of medicines.

ALNYLAM PHARMACEUTICALS was NEW CLINICAL PROGRAMS ADDED IN 2021 and 2.4 BILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AT YEAR-END 2021.

As on 2022, ALNYLAM PHARMACEUTICALS has 2,002 employees.

ALNYLAM PHARMACEUTICALS annual revenue generated for period ending Dec-2022 was 1,037 million USD.

ALNYLAM PHARMACEUTICALS annual net loss generated for period ending Dec-2022 was -1,131 (Loss) million USD.

ALNYLAM PHARMACEUTICALS total number of employees in 2021 was 1,850 and 23 countries with Alnylam offices.

ALNYLAM PHARMACEUTICALS annual revenue generated for period ending Jun-2022 was 844 million USD.

ALNYLAM PHARMACEUTICALS annual net income generated for period ending Jun-2022 was -852 million USD.

Annual Results Summary

ALNYLAM PHARMACEUTICALS - Annual Result Summary - in Million USD

Year Ending:	Total Revenue	Gross Profit	Operating Income	Net Income
Dec-2022	1,037	868	-785 (Loss)	-1,131 (Loss)
Dec-2021	844	704	-708 (Loss)	-852 (Loss)
Dec-2020	493	414	(828.4) (Loss)	(858.3) (Loss)
Dec-2019	219	194	(939.4) (Loss)	(886.1) (Loss)
Dec-2018	75	73	(814.7) (Loss)	(761.5) (Loss)
Dec-2017	90	90	(500.1) (Loss)	(490.9) (Loss)

Founded Year

2002

Institutional Investors

Top 30 Institutional Holder Names in ALNYLAM PHARMACEUTICALS as on SEP-30-2023

RANK	INSTITUTION NAME	DATE	SHARES HELD	CHANGE (SHARES)	CHANGE (%)	VALUE (IN 1,000S)
1	CAPITAL WORLD INVESTORS	09/30/2023	1,65,29,308	31,757	0.19%	$2,706,344
2	VANGUARD GROUP INC	09/30/2023	1,16,56,831	30,608	0.26%	$1,908,573
3	FMR LLC	09/30/2023	1,12,81,406	-12,11,094	-9.70%	$1,847,105
4	BLACKROCK INC.	09/30/2023	83,93,004	6,842	0.08%	$1,374,187
5	BAILLIE GIFFORD & CO	09/30/2023	81,63,139	-2,29,077	-2.73%	$1,336,551
6	WELLINGTON MANAGEMENT GROUP LLP	09/30/2023	64,31,814	3,64,021	6.00%	$1,053,081
7	PRICE T ROWE ASSOCIATES INC /MD/	09/30/2023	39,25,004	39,468	1.02%	$642,641
8	DODGE & COX	09/30/2023	37,47,155	-42,370	-1.12%	$613,522
9	T. ROWE PRICE INVESTMENT MANAGEMENT, INC.	09/30/2023	33,98,859	1,61,235	4.98%	$556,495
10	CAPITAL INTERNATIONAL INVESTORS	09/30/2023	30,97,843	2,17,200	7.54%	$507,210
11	JPMORGAN CHASE & CO	09/30/2023	30,86,846	-46,128	-1.47%	$505,409
12	STATE STREET CORP	09/30/2023	28,99,513	7,266	0.25%	$474,737
13	CAPITAL RESEARCH GLOBAL INVESTORS	09/30/2023	27,83,843	4,29,082	18.22%	$455,799
14	GEODE CAPITAL MANAGEMENT, LLC	09/30/2023	18,39,505	37,483	2.08%	$301,182
15	RTW INVESTMENTS, LP	09/30/2023	16,83,362	0	0%	$275,617
16	MORGAN STANLEY	09/30/2023	12,09,383	-6,71,423	-35.70%	$198,012
17	NORGES BANK	12/31/2022	10,12,846	-2,05,338	-16.86%	$165,833
18	AVORO CAPITAL ADVISORS LLC	09/30/2023	10,11,111	-93,889	-8.50%	$165,549
19	BELLEVUE GROUP AG	09/30/2023	8,94,345	-5,305	-0.59%	$146,431
20	BANK OF NEW YORK MELLON CORP	09/30/2023	8,37,084	61,488	7.93%	$137,056
21	NORTHERN TRUST CORP	09/30/2023	7,97,700	25,230	3.27%	$130,607
22	LEGAL & GENERAL GROUP PLC	09/30/2023	7,94,671	-3,718	-0.47%	$130,111
23	PICTET ASSET MANAGEMENT HOLDING SA	09/30/2023	7,90,755	7,90,755	New	$129,470
24	UBS ASSET MANAGEMENT AMERICAS INC	09/30/2023	7,74,476	1,00,598	14.93%	$126,805
25	AMERIPRISE FINANCIAL INC	09/30/2023	7,06,200	80,862	12.93%	$115,626
26	MASSACHUSETTS FINANCIAL SERVICES CO /MA/	09/30/2023	6,88,228	15,831	2.35%	$112,684
27	PICTET ASSET MANAGEMENT SA	06/30/2023	6,48,546	44,471	7.36%	$106,186
28	LOOMIS SAYLES & CO L P	09/30/2023	6,25,401	-19,742	-3.06%	$102,397
29	AMUNDI	09/30/2023	6,14,359	-60,409	-8.95%	$100,589
30	GILDER GAGNON HOWE & CO LLC	09/30/2023	5,94,979	-3,717	-0.62%	$97,416